ES2630037T3 - Suspensión farmacéutica - Google Patents

Suspensión farmacéutica Download PDF

Info

Publication number
ES2630037T3
ES2630037T3 ES09768284.3T ES09768284T ES2630037T3 ES 2630037 T3 ES2630037 T3 ES 2630037T3 ES 09768284 T ES09768284 T ES 09768284T ES 2630037 T3 ES2630037 T3 ES 2630037T3
Authority
ES
Spain
Prior art keywords
sediment
volume
molecular weight
peg
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09768284.3T
Other languages
English (en)
Spanish (es)
Inventor
Bhagwati P. Kabra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2630037T3 publication Critical patent/ES2630037T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09768284.3T 2008-12-05 2009-12-03 Suspensión farmacéutica Active ES2630037T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12008108P 2008-12-05 2008-12-05
US120081P 2008-12-05
PCT/US2009/066570 WO2010065730A2 (en) 2008-12-05 2009-12-03 Pharmaceutical suspension

Publications (1)

Publication Number Publication Date
ES2630037T3 true ES2630037T3 (es) 2017-08-17

Family

ID=41562672

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09768284.3T Active ES2630037T3 (es) 2008-12-05 2009-12-03 Suspensión farmacéutica

Country Status (17)

Country Link
US (1) US9707173B2 (https=)
EP (1) EP2364137B1 (https=)
JP (1) JP5661640B2 (https=)
AR (1) AR074423A1 (https=)
AU (1) AU2009322355B2 (https=)
CA (1) CA2745123C (https=)
CY (1) CY1119038T1 (https=)
DK (1) DK2364137T3 (https=)
ES (1) ES2630037T3 (https=)
HR (1) HRP20170959T1 (https=)
HU (1) HUE034662T2 (https=)
LT (1) LT2364137T (https=)
PL (1) PL2364137T3 (https=)
PT (1) PT2364137T (https=)
SI (1) SI2364137T1 (https=)
TW (1) TW201023912A (https=)
WO (1) WO2010065730A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8912236B2 (en) 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
MX2011008680A (es) * 2009-03-03 2011-09-08 Alcon Res Ltd Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
US20120022149A1 (en) * 2010-07-21 2012-01-26 Chowhan Masood A Pharmaceutical composition with enhanced solubility characteristics
WO2012016569A1 (en) 2010-08-05 2012-02-09 Conrig Pharma Aps Deuterated tandospirone derivatives as 5-ht1a receptor agonists
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
CN108434116B (zh) * 2017-02-16 2021-05-11 人福普克药业（武汉）有限公司 贝萨罗汀软胶囊及其制备方法
SI3943070T1 (sl) 2017-07-14 2024-03-29 Janssen Pharmaceutica Nv, Dolgo delujoče formulacije bedakilina
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
TWI798452B (zh) * 2019-06-17 2023-04-11 晶碩光學股份有限公司 隱形眼鏡產品
CN113018271B (zh) * 2019-12-25 2022-08-09 四川科瑞德制药股份有限公司 一种坦度螺酮药物组合物及其制备方法和用途
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
WO2021222117A1 (en) 2020-04-27 2021-11-04 Ocular Therapeutix, Inc. Methods of treating allergic conjunctivitis
US20220105103A1 (en) * 2020-10-05 2022-04-07 Somerset Therapeutics, Llc Safe use of brinzolamide and brimonidine compositions with enhanced benzalkonium chloride content
US20220105101A1 (en) 2020-10-05 2022-04-07 Somerset Therapeutics, Llc Efficient brinzolamide and brimonidine compositions
EP4565242A1 (en) * 2023-05-11 2025-06-11 Akums Drugs And Pharmaceuticals Limited Benzalkonium chloride free ophthalmic formulation

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856919A (en) * 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4836986A (en) * 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5037647A (en) * 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5206267A (en) * 1991-05-09 1993-04-27 Morton Shulman Pain controlling composition and method of preparation
US5338732A (en) * 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
US5932572A (en) 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
US5300287A (en) * 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
ES2141775T3 (es) * 1993-04-16 2000-04-01 Wakamoto Pharma Co Ltd Composicion medicinal a base de agua termicamente gelificante reversible.
EP0782850A4 (en) * 1994-10-13 1998-03-04 Wakamoto Pharma Co Ltd LYOPHILIZED PREPARATION FOR PRODUCING A REVERSIBLE THERMOGELING MEDICINAL WATER-BASED
PT948357E (pt) * 1996-12-13 2002-10-31 Alcon Lab Inc Utilizacao de amino alcoois de baixo peso molecular em composicoes oftalmicas
JPH10287552A (ja) * 1997-04-11 1998-10-27 Kobayashi Seiyaku Kogyo Kk 滅菌されたアシクロビル水性懸濁点眼剤及びその製造方法
CA2264290C (en) 1997-07-29 2005-11-29 Alcon Laboratories, Inc. Conditioning solutions for contact lens care
NZ517556A (en) * 1999-09-06 2003-08-29 Ono Pharmaceutical Co N-[o-(p-pivaloyloxybenzenesulphonyl-amino)benzoyl]glycine as preventive and therapeutic agents for eye diseases
WO2001022936A1 (en) 1999-09-24 2001-04-05 Alcon Universal Ltd. Topical suspension formulations containing ciprofloxacin and dexamethasone
WO2001087262A2 (en) * 2000-05-15 2001-11-22 Pharmacia Italia S.P.A. Stabilized steroidal suspension
EP1318787A2 (en) 2000-07-26 2003-06-18 Alcon Inc. Pharmaceutical suspension compositions lacking a polymeric suspending agent
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
RU2295346C2 (ru) * 2001-09-21 2007-03-20 Алькон, Инк. Способ лечения инфекций среднего уха
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
WO2004000284A1 (en) * 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
JP4810427B2 (ja) 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
SI1755616T1 (sl) * 2004-04-08 2014-04-30 Eye Co Pty Ltd. Zdravljenje eksudativne retinopatije z mineralkortikoidi
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CA2607608A1 (en) 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
PL1906916T3 (pl) 2005-05-10 2009-02-27 Alcon Inc Zawiesina do oczu obejmująca lek okulistyczny, poloksaminę i glikolowy środek regulujący toniczność, zastosowanie wymienionej kompozycji do wytwarzania leku do leczenia zaburzeń wzroku
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
JP2009521493A (ja) * 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
AU2007333959A1 (en) * 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
JP2010534201A (ja) 2007-07-20 2010-11-04 アルコン，インコーポレイテッド 受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の目への送達のための医薬製剤
EP2072564B1 (de) 2007-12-19 2013-07-03 Sika Technology AG Einkomponentiger, feuchtigkeitshärtender Polymerschaum
JP5155767B2 (ja) 2008-08-04 2013-03-06 国立大学法人大阪大学 ガス検知素子
MX2011008680A (es) 2009-03-03 2011-09-08 Alcon Res Ltd Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.

Also Published As

Publication number Publication date
JP5661640B2 (ja) 2015-01-28
AR074423A1 (es) 2011-01-19
US20100144719A1 (en) 2010-06-10
PL2364137T3 (pl) 2017-09-29
WO2010065730A2 (en) 2010-06-10
HUE034662T2 (en) 2018-02-28
US9707173B2 (en) 2017-07-18
SI2364137T1 (sl) 2017-07-31
DK2364137T3 (en) 2017-07-10
AU2009322355B2 (en) 2015-11-05
PT2364137T (pt) 2017-07-10
WO2010065730A3 (en) 2011-04-14
CY1119038T1 (el) 2018-01-10
JP2012511009A (ja) 2012-05-17
TW201023912A (en) 2010-07-01
EP2364137A2 (en) 2011-09-14
EP2364137B1 (en) 2017-03-29
HRP20170959T1 (hr) 2017-09-22
AU2009322355A1 (en) 2010-06-10
LT2364137T (lt) 2017-06-26
CA2745123C (en) 2018-11-13
CA2745123A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
ES2630037T3 (es) Suspensión farmacéutica
Vigani et al. Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes
Wang et al. Antibacterial effect of chitosan and its derivative on Enterococcus faecalis associated with endodontic infection
Ouyang et al. A facile and general method for synthesis of antibiotic-free protein-based hydrogel: Wound dressing for the eradication of drug-resistant bacteria and biofilms
Chang et al. Liposomal dexamethasone–moxifloxacin nanoparticle combinations with collagen/gelatin/alginate hydrogel for corneal infection treatment and wound healing
Khalil et al. Noninvasive biodegradable nanoparticles-in-nanofibers single-dose ocular insert: in vitro, ex vivo and in vivo evaluation
Zhou et al. Development of fish collagen/bioactive glass/chitosan composite nanofibers as a GTR/GBR membrane for inducing periodontal tissue regeneration
Cassano et al. Gel-based materials for ophthalmic drug delivery
González-Sánchez et al. Silver nanoparticle based antibacterial methacrylate hydrogels potential for bone graft applications
Castillo et al. Recent advances toward the use of mesoporous silica nanoparticles for the treatment of bacterial infections
He et al. Development of an antimicrobial peptide-loaded mineralized collagen bone scaffold for infective bone defect repair
ES2637028T3 (es) Composiciones farmacéuticas que tienen biodisponibilidad deseable
Ibrahim et al. Bioactive and elastic nanocomposites with antimicrobial properties for bone tissue regeneration
Sahal et al. Electrospun essential oil-polycaprolactone nanofibers as antibiofilm surfaces against clinical Candida tropicalis isolates
Fu et al. Synergistic and long-lasting wound dressings promote multidrug-resistant Staphylococcus aureus-infected wound healing
Jia et al. Development of a Doxycycline Hydrochloride‐Loaded Electrospun Nanofibrous Membrane for GTR/GBR Applications
CN117624172B (zh) 一种有机分子笼、有机分子笼纳米酶滴眼液及其制备方法
Cho et al. In‐vitro evaluation of a ciprofloxacin‐and ivacaftor‐coated sinus stent against Pseudomonas aeruginosa biofilms
Grützner et al. Enzyme-responsive nanocomposites for wound infection prophylaxis in burn management: in vitro evaluation of their compatibility with healing processes
Xu et al. Tuning osteoporotic macrophage responses to favour regeneration by Cu-bearing titanium alloy in Porphyromonas gingivalis lipopolysaccharide-induced microenvironments
Karahaliloglu et al. In vitro evaluation of bone cements impregnated with selenium nanoparticles stabilized by phosphatidylcholine (PC) for application in bone
Hasan et al. Controlled and localized nitric oxide precursor delivery from chitosan gels to Staphylococcus aureus biofilms
Khodaverdi et al. Effects of formulation properties on sol–gel behavior of chitosan/glycerolphosphate hydrogel
CN115671298A (zh) 一种ros响应的抗菌药物纳米载体及其制备方法
Gao et al. Study on the local anti-osteoporosis effect of polaprezinc-loaded antioxidant electrospun membrane